Active	Status	Sponsor type	Region	Phase	Filter
5 Active 5 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grisanti, Salvatore
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().	Recruiting	3	560	Europe, Canada, Japan, US, RoW	sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel	Seagen Inc.	Carcinoma, Non-Small-Cell Lung	07/26	07/28
Spencer, NCT04187404 / 2019-003396-19: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma	Terminated	1/2	70	Europe, US	EO2401, Nivolumab	Enterome	Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma	05/24	10/24
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced	Recruiting	N/A	600	Europe		MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa	Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I	06/25	06/25